FDA Brief

Warning letters Drugs

FDA warning letter to

Macsen Drugs

High riskIssued Mar 5, 2025Posted Jul 29, 2025Center for Drug Evaluation and Research (CDER)

FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.

What happened

FDA inspected Macsen Drugs from September 2 to 6, 2024. FDA found that the quality unit released active pharmaceutical ingredient (API) lots it had identified as impacted by a December 2022 fire for U.S. distribution, and that stability chambers had power failures of up to 40 hours without data loggers or data showing API quality through expiry. FDA reviewed the firm’s September 27, 2024 response and called it inadequate.

What FDA found

  1. The quality unit (the group responsible for release decisions) released API lots that its incident report identified as impacted by a December 2022 fire for U.S. distribution.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. The quality unit did not ensure stability data supported API retest or expiry dates and storage conditions.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA tells Macsen to respond in writing within 15 working days with what it has done to correct the deviations and prevent recurrence; if it cannot complete actions, it must explain delays and give a schedule. FDA also asks for a comprehensive quality-unit remediation plan, an independent stability-program assessment and corrective action plan, and an action plan for affected U.S. API lots, including customer notifications and recalls.

Who should pay attention

  • drugmakers that use Macsen APIs in U.S. products
  • brands and contractors sourcing APIs from this facility
  • quality teams managing supplier qualification and recalls

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  4. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk